SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Published on 08/07/2025 at 18:08 | prnewswire.co.uk
Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour View original content:https://www.prnewswire.co.uk/news-releases/synox-therapeutics-announces-75m-series-b-round-to-fund-phase-3-trial-of-potential-best-in-class-treatment-for-tgct-302122321.html
en | boerse | 67925895 |
